Last reviewed · How we verify

NCT06354686

Characterizing the Scalp Tolerability of TMS

Completed NA Last updated 6 April 2026
What this trial tests

NA trial testing TMS Tolerability in Healthy in 20 participants. Completed in 14 November 2024.

Timeline
14 June 2024
Primary endpoint
14 November 2024
14 November 2024

Quick facts

Lead sponsorFlorida State University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Enrollment20
Start date14 June 2024
Primary completion14 November 2024
Estimated completion14 November 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Florida State University

Who can join

18 and older, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective is to characterize the tolerability of TMS by scalp location (over parietal, motor, modified Beam F3 prefrontal, THREE-D prefrontal, orbitofrontal, and medial prefrontal) and stimulation parameters (single pulse, 10 Hz, theta burst). The secondary objective is to evaluate the knee as a surrogate location to safely trial tolerability of novel TMS parameters.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Healthy

Currently open trials in the same condition.

Other Florida State University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06354686.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing